Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000547384 | SCV000628637 | likely benign | Neurofibromatosis, type 1 | 2024-10-15 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001770412 | SCV002004264 | uncertain significance | not provided | 2023-11-01 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed as a germline variant in an individual with juvenile myelomonocytic leukemia in the published literature (PMID: 23832011); This variant is associated with the following publications: (PMID: 23832011, 36243179) |
Genome- |
RCV000547384 | SCV002560497 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002341272 | SCV002643977 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2024-09-09 | criteria provided, single submitter | clinical testing | The p.Y1657C variant (also known as c.4970A>G), located in coding exon 36 of the NF1 gene, results from an A to G substitution at nucleotide position 4970. The tyrosine at codon 1657 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |